Combo of Approved Agents Active in High-Risk Large B-Cell Lymphoma

Published Date: 28 Jun 2024

Our panel of experts discusses mosunetuzumab/polatuzumab vedotin for relapsed/refractory patients

Read Full News

Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

The clinical trial of ENZAMET shows promise as a treatment for prostate cancer.

2.

Lung Cancer Screening Rates in Eligible Adults Remain Low, Uneven

3.

TikTok creators perform 'roles' when sharing their hereditary cancer stories, shaping the health information they share

4.

It Is Not Just the Royals Who Go Through Cancer.

5.

Joe Biden has prostate cancer with bone spread. An oncologist explains what you need to know


© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot